
|Articles|August 4, 2003
New once-daily HIV drug helps with patient compliance
Emtriva is the first once-daily nucleoside reverse transcriptase inhibitor to receive a nod of approval from the FDA.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
PCV21 Shows Cost Effectiveness Compared With PCV15, PCV13, and PPSV23
2
Lower Baseline BMI Predicts Weight Loss At 6 Months With Liraglutide
3
Providers, Patients Show Favorable Perception of Remdesivir During COVID-19 Pandemic
4


























































































































































